Summary of Study ST003362

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002088. The data can be accessed directly via it's Project DOI: 10.21228/M8QJ9B This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003362
Study TitleMetabolomics analysis of Glioblastoma (GBM) cell line U251 labeled by 13C-glutamine after treatment with pimozide
Study SummaryGlioblastoma (GBM) cell line U251 was treated with antipsychotic drug pimozide (3 uM) for 24 hr, and then labeled with 13C-glutamine (2 mM) for 1 hr. Cells were collected and extracted for metabolites and analyzed by LC-MS. Our data showed that pimozide treatment significantly increased 13C-labeled glutamine uptake and subsequent consumption, including anaplerosis of metabolites for tricarboxylic acid (TCA) cycle and de novo fatty acid synthesis derived from glutamine-mediated reductive carboxylation process.
Institute
Ohio State University
Last NameGuo
First NameDeliang
AddressDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.
Emaildeliang.guo@osumc.edu
Phone6143663774
Submit Date2024-07-29
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2024-08-05
Release Version1
Deliang Guo Deliang Guo
https://dx.doi.org/10.21228/M8QJ9B
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Combined analysis:

Analysis ID AN005504 AN005505 AN005506 AN005507 AN005508
Analysis type MS MS MS MS MS
Chromatography type Reversed phase Reversed phase HILIC HILIC Reversed phase
Chromatography system Thermo Dionex Ultimate 3000 Thermo Dionex Ultimate 3000 Thermo Dionex Ultimate 3000 Thermo Dionex Ultimate 3000 Thermo Dionex Ultimate 3000
Column Waters ACQUITY UPLC HSS T3 (150 x 2.1mm,1.8um) Waters ACQUITY UPLC HSS T3 (150 x 2.1mm,1.8um) SeQuant ZIC-cHILIC (150 x 2.1mm, 3 um) SeQuant ZIC-cHILIC (150 x 2.1mm, 3 um) Waters ACQUITY UPLC BEH C8 (100 x 2.1mm,1.7um)
MS Type ESI ESI ESI ESI ESI
MS instrument type Orbitrap Orbitrap Orbitrap Orbitrap Orbitrap
MS instrument name Thermo Q Exactive HF hybrid Orbitrap Thermo Q Exactive HF hybrid Orbitrap Thermo Q Exactive HF hybrid Orbitrap Thermo Q Exactive HF hybrid Orbitrap Thermo Q Exactive HF hybrid Orbitrap
Ion Mode POSITIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE
Units Counts Counts Counts Counts Counts

MS:

MS ID:MS005230
Analysis ID:AN005504
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:FullMS data was collected under both positive and negative mode. XCMS software was used for spectrum deconvolution and MetSign software for metabolite identification, cross-sample peak list alignment, normalization, and statistical analysis.To identify metabolites, 2DLC-MS/MS data was first matched to our in-house database that contains parent ion m/z, MS/MS spectra, and retention time of authentic standards. Threshold for spectral similarity was set ≥ 0.4, while thresholds of retention time difference and m/z variation window were respectively set ≤ 0.15 min and ≤ 5 ppm. 2DLC-MS/MS data without a match with the metabolites in the in-house database were further analyzed using Compound Discoverer software (v 2.0, Thermo Fisher Scientific, Germany), where MS/MS spectra similarity score threshold was set ≥ 40 with a maximum score of 100.
Ion Mode:POSITIVE
  
MS ID:MS005231
Analysis ID:AN005505
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:FullMS data was collected under both positive and negative mode. XCMS software was used for spectrum deconvolution and MetSign software for metabolite identification, cross-sample peak list alignment, normalization, and statistical analysis.To identify metabolites, 2DLC-MS/MS data was first matched to our in-house database that contains parent ion m/z, MS/MS spectra, and retention time of authentic standards. Threshold for spectral similarity was set ≥ 0.4, while thresholds of retention time difference and m/z variation window were respectively set ≤ 0.15 min and ≤ 5 ppm. 2DLC-MS/MS data without a match with the metabolites in the in-house database were further analyzed using Compound Discoverer software (v 2.0, Thermo Fisher Scientific, Germany), where MS/MS spectra similarity score threshold was set ≥ 40 with a maximum score of 100.
Ion Mode:NEGATIVE
  
MS ID:MS005232
Analysis ID:AN005506
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:FullMS data was collected under negative mode. XCMS software was used for spectrum deconvolution and MetSign software for metabolite identification, cross-sample peak list alignment, normalization, and statistical analysis.To identify metabolites, 2DLC-MS/MS data was first matched to our in-house database that contains parent ion m/z, MS/MS spectra, and retention time of authentic standards. Threshold for spectral similarity was set ≥ 0.4, while thresholds of retention time difference and m/z variation window were respectively set ≤ 0.15 min and ≤ 5 ppm. 2DLC-MS/MS data without a match with the metabolites in the in-house database were further analyzed using Compound Discoverer software (v 2.0, Thermo Fisher Scientific, Germany), where MS/MS spectra similarity score threshold was set ≥ 40 with a maximum score of 100.
Ion Mode:POSITIVE
  
MS ID:MS005233
Analysis ID:AN005507
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:FullMS data was collected under negative mode. XCMS software was used for spectrum deconvolution and MetSign software for metabolite identification, cross-sample peak list alignment, normalization, and statistical analysis.To identify metabolites, 2DLC-MS/MS data was first matched to our in-house database that contains parent ion m/z, MS/MS spectra, and retention time of authentic standards. Threshold for spectral similarity was set ≥ 0.4, while thresholds of retention time difference and m/z variation window were respectively set ≤ 0.15 min and ≤ 5 ppm. 2DLC-MS/MS data without a match with the metabolites in the in-house database were further analyzed using Compound Discoverer software (v 2.0, Thermo Fisher Scientific, Germany), where MS/MS spectra similarity score threshold was set ≥ 40 with a maximum score of 100.
Ion Mode:NEGATIVE
  
MS ID:MS005234
Analysis ID:AN005508
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:FullMS data was collected under negative mode. XCMS software was used for spectrum deconvolution and MetSign software for metabolite identification, cross-sample peak list alignment, normalization, and statistical analysis.To identify metabolites, 2DLC-MS/MS data was first matched to our in-house database that contains parent ion m/z, MS/MS spectra, and retention time of authentic standards. Threshold for spectral similarity was set ≥ 0.4, while thresholds of retention time difference and m/z variation window were respectively set ≤ 0.15 min and ≤ 5 ppm. 2DLC-MS/MS data without a match with the metabolites in the in-house database were further analyzed using Compound Discoverer software (v 2.0, Thermo Fisher Scientific, Germany), where MS/MS spectra similarity score threshold was set ≥ 40 with a maximum score of 100.
Ion Mode:NEGATIVE
  logo